表柔比星和丝裂霉素膀胱灌注预防浅表性膀胱癌复发的临床研究  

THE CLINICAL RESEARCH ON PREVENTING THE RECURRENCE OF SUPERFICIAL BLADDER CACER BY INTRAVESICAL INFUSION WITH EPIRUBICIN AND MITOMYCIN

作　　者：梁健铭[1,2] 杨占斌[3] 汪小明[3] 莫林键[3] 虞军[3] 

机构地区：[1]广西医科大学研究生学院 [2]广西中医药大学附属瑞康医院器官移植泌尿外科 [3]广西医科大学第一附属医院泌尿外科,南宁530021

出　　处：《广西医科大学学报》2015年第3期395-397,共3页Journal of Guangxi Medical University

基　　金：广西医疗卫生重点科研课题(No.重200909)

摘　　要：目的：观察不同剂量和不同次数的表柔比星和丝裂霉素膀胱灌注预防浅表性膀胱癌复发的临床疗效.方法：将入选病人随机分为A,B,C,D4组.A组病人术后6h予表柔比星80 mg单次灌注;B组病人术后1周灌注表柔比星20 mg,每周灌注1次,8～10次后改为每月1次,至术后1年.C组病人术后6h予丝裂霉素80 mg单次灌注;D组病人术后1周灌注丝裂霉素20 mg,每周灌注1次,8～10次后改为每月1次,至术后1年.随访2年,观察无病间期、肿瘤复发及不良反应情况.结果：A,B,C,D4组2年的无病间期差异无统计学意义（P＞0.05）,4组病人术后2年复发率分别为38.2％,37.8％,39.1％和36.3％,差异无统计学意义（P＞0.05）,A组与C组不良反应率明显低于B组与D组,差异有统计学意义（P＜0.05）.结论：表柔比星和丝裂霉素单次高剂量与多次常规剂量灌注治疗预防浅表性膀胱癌术后复发的临床疗效无明显差异,单次灌注的不良反应率低于多次灌注.Objective： To investigate the clinical efficiency on preventing recurrence of primary superficial bladder cancer by intravesical infusion with epirubicin and mitomycin. Methods： The patients were randomly divide into A,B,C and D for four groups. A group＇s patients were received 80 mg epirubicin one time after operation 6 h later; B group＇s patients received 20 mg epirubicin one time per week after surgery one week later,after 8-10 times, the therapeutic program was changed into once a month until opertation 1 year; C group＇s patients were received 80 mg mitomycin one time after operation 6 h. D group＇s patients were received 20 mg mitomycin one time per week afer surgery a week. And the therapeutic program of D group was changed into once a month until operation 1 year after receiving mitomycin 8-10 times. All patients were followed up for 2 years and observed their situation about disease-free time, tumor recurrence and adverse reaction. Results： There was no difference in the disease-free time of four groups after following up 2 years（ P 〉0.05）. The recurrence rates of A,B, C, D group respectively were 38.2%,37.8%, 39.1% ,36.3% and these dates showed there were not significantly different（ P 〉0.05）. Side effects of A and C group were significant lower than that of B and D group（ P 〈0. 05）. Conclusion：For epirubicin and mitomycin, there was no difference between the effect of signgle high dose and the effect of multiple conventional dose on prevention superficical bladder cancer recurrence,and the rate of adverse effect of single infusion was lower than that of multiple infusion groups.

关 键 词：膀胱肿瘤 肿瘤复发 表柔比星 丝裂霉素 

分 类 号：R737.14[医药卫生—肿瘤]